352.4 ð ç« æ«éèš Summary
352.4.1 ð äžå¥è©±çžœçµ
Celiac disease = autoimmune enteropathy triggered by gluten in HLA-DQ2/DQ8 susceptible (necessary but not sufficient); ~ 1% Western, ~ 0.5% Asian (increasing)ïŒclinical spectrumïŒclassic GI (diarrhea, malabsorption, weight loss, failure to thrive) + non-classic (iron deficiency anemia most common, osteoporosis, infertility, dermatitis herpetiformis pathognomonic with IgA deposits, neurologic ataxia/neuropathy, fatigue, depression, aphthous stomatitis, dental enamel) + silentïŒassociatedïŒT1DM (5-10% have celiac), autoimmune thyroid, IgA deficiency (need IgG-based serology), Down + Turner, PBC, AIH, SjögrenïŒdiagnosisïŒanti-tissue transglutaminase IgA (preferred screen) + total IgA + duodenal biopsy (gold standard â Marsh classification 1-3c with villous atrophy + crypt hyperplasia + IEL); on gluten diet for testingïŒESPGHAN 2020 may avoid biopsy if high titer + EMA + HLA in select pediatricïŒtreatmentïŒlifelong strict gluten-free diet (GFD) â avoid wheat/barley/rye; dietitian; 70-80% histological + 90% symptom improvementïŒrefractory celiacïŒType I (no clonal IEL) vs Type II (clonal IEL â EATL risk); budesonide + IS + biologics + autologous SCTïŒother malabsorption syndromesïŒ(1) mucosal (celiac, Crohnâs, tropical sprue â tetracycline + folate, Whipple disease â T. whipplei + PAS+ macrophages + IV ceftriaxone â TMP-SMX 1 year, AIDS enteropathy); (2) pancreatic insufficiency (chronic pancreatitis, CF, cancer) â fecal elastase < 200 + PERT + ADEK vitamins; (3) bile salt deficiency (cholestasis, ileal resection); (4) SIBO (small intestinal bacterial overgrowth) â diabetic enteropathy + scleroderma + post-surgery + achlorhydria; hydrogen breath test diagnosis + rifaximin 550 TID à 14 d treatment; (5) lactose intolerance â primary (Asians, Africans, Native Americans) + secondary; hydrogen breath test + avoidance + Lactaid + yogurt; 2024 emerging celiac therapiesïŒlatiglutenase + larazotide acetate + cell-basedã
352.4.2 ð æ²»ç粟èŠ
- celiac treatmentïŒlifelong strict gluten-free diet (GFD) â avoid wheat/barley/rye; oats acceptable (cross-contamination risk); < 20 ppm gluten labeled; dietitian guidance + support groups
- dermatitis herpetiformisïŒdapsone + strict GFD; may eventually allow dapsone discontinuation
- refractory celiac type IIïŒbudesonide + AZA + biologics + autologous SCT for EATL prevention/treatment
- tropical sprueïŒtetracycline + folate + vitamin B12 supplementation
- Whipple diseaseïŒIV ceftriaxone à 2-4 weeks â oral TMP-SMX à 1 year; PCR + PAS+ confirms
- pancreatic insufficiencyïŒPERT (pancrelipase) with all meals (25,000-75,000 units lipase per meal) + ADEK vitamins supplementation
- SIBOïŒrifaximin 550 mg TID à 14 days first-line + alternatives (norfloxacin, metronidazole, cipro); re-treatment for recurrence; prokinetics + treat underlying motility/structural
- lactose intoleranceïŒlactose restriction + Lactaid enzyme supplements + lactose-free dairy + yogurt with live cultures often tolerated
- bile acid diarrheaïŒcholestyramine, colesevelam
- short bowel syndromeïŒspecialized nutrition + teduglutide (GLP-2 analog) + TPN if severe
352.4.3 ð¯ ç§é«åž«çèåæé
- celiac HLA-DQ2 (95%) + HLA-DQ8 (5%) necessary but not sufficient â useful negative predictive value rules out; positive doesnât confirm
- celiac serology workflowïŒanti-tTG IgA (preferred screen) + total IgA; if IgA deficient â anti-tTG IgG or anti-DGP IgG; EMA confirmatory expensive
- celiac duodenal biopsy gold standardïŒMarsh 1 (IEL) â Marsh 2 (+ crypt hyperplasia) â Marsh 3a-c (+ villous atrophy partial â subtotal â total); must be on gluten for valid testing
- dermatitis herpetiformis pathognomonic for celiacïŒpruritic vesicular eruption + IgA deposits at dermal papillae; dapsone + GFD
- celiac associated conditionsïŒT1DM (5-10% have celiac), autoimmune thyroid, IgA deficiency (need IgG-based serology), Down syndrome, Turner syndrome, PBC, AIH, Sjögren â screen if any
- refractory celiac Type II (clonal IEL)ïŒsignificant risk for EATL (enteropathy-associated T-cell lymphoma) â aggressive workup + treatment
- Whipple diseaseïŒT. whipplei + multi-system (arthralgia + GI + neurologic + cardiac + ocular) + PAS-positive macrophages in lamina propria + PCR; IV ceftriaxone à 2-4 weeks â oral TMP-SMX à 1 year prevents relapse
- SIBO key risk factorsïŒdiabetic enteropathy, scleroderma, post-bariatric surgery, Roux-en-Y, diverticula, Crohnâs, achlorhydria (PPI long-term), cirrhosis, elderly
- SIBO diagnosisïŒhydrogen breath test (lactulose or glucose) â most common; methane breath test for methanogens; jejunal aspirate gold standard but rarely done; treatment rifaximin 550 TID à 14 d
- lactose intolerance regional patternsïŒprimary lactase deficiency (Asians, Africans, Native Americans, Hispanic â lactase persistence rare) vs secondary (post-enteritis, celiac, Crohnâs â may recover); hydrogen breath test + restriction + Lactaid